1 |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
|
2 |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
|
3 |
Heximer SP, Knutsen RH, Sun X, et al. Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice[J]. J Clin Invest, 2003, 111(4): 445-452.
|
4 |
Taymans JM, Wintmolders C, Te Riele P, et al. Detailed localization of regulator of G protein signaling 2 messenger ribonucleic acid and protein in the rat brain[J]. Neuroscience, 2002, 114(1): 39-53.
|
5 |
Lyu JH, Park DW, Huang B, et al. RGS2 suppresses breast cancer cell growth via a MCPIP1-dependent pathway[J]. J Cell Biochem, 2015, 116(2): 260-267.
|
6 |
Linder A, Hagberg Thulin M, Damber JE, et al. Analysis of regulator of G-protein signalling 2 (RGS2) expression and function during prostate cancer progression[J]. Sci Rep, 2018, 8(1): 17259.
|
7 |
Schwäble J, Choudhary C, Thiede C, et al. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation[J]. Blood, 2005, 105(5): 2107-2114.
|
8 |
Sjögren B, Swaney S, Neubig RR. FBXO44-mediated degradation of RGS2 protein uniquely depends on a cullin 4B/DDB1 complex[J]. PLoS One, 2015, 10(5): e0123581.
|
9 |
Ding L, Niu C, Zheng Y, et al. FHL1 interacts with oestrogen receptors and regulates breast cancer cell growth[J]. J Cell Mol Med, 2011, 15(1): 72-85.
|
10 |
Kandola MK, Sykes L, Lee YS, et al. EP2 receptor activates dual G protein signaling pathways that mediate contrasting proinflammatory and relaxatory responses in term pregnant human myometrium[J]. Endocrinology, 2014, 155(2): 605-617.
|
11 |
Xie GX, Palmer PP. How regulators of G protein signa-ling achieve selective regulation[J]. J Mol Biol, 2007, 366(2): 349-365.
|
12 |
Santos-Otte P, Leysen H, van Gastel J, et al. G protein-coupled receptor systems and their role in cellular senescence[J]. Comput Struct Biotechnol J, 2019, 17: 1265-1277.
|
13 |
Cao X, Qin J, Xie Y, et al. Regulator of G-protein signa-ling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells[J]. Oncogene, 2006, 25(26): 3719-3734.
|
14 |
Siderovski DP, Heximer SP, Forsdyke DR. A human gene encoding a putative basic helix-loop-helix phosphoprotein whose mRNA increases rapidly in cycloheximide-treated blood mononuclear cells[J]. DNA Cell Biol, 1994, 13(2): 125-147.
|
15 |
Hurst JH, Mendpara N, Hooks SB. Regulator of G-protein signalling expression and function in ovarian cancer cell lines[J]. Cell Mol Biol Lett, 2009, 14(1): 153-174.
|
16 |
刘鹏, 李永宁, 潘耀振. G蛋白信号调节蛋白2在肝癌组织中的表达及临床意义[J]. 贵州医药, 2018, 42(2): 157-159.
|
|
Liu P, Li YN, Pan YZ. Expression and clinical significance of the regulator of G-protein signaling 2 in liver cancer[J]. Guizhou Med J, 2018, 42(2): 157-159.
|
17 |
Harrigan JA, Jacq X, Martin NM, et al. Deubiquitylating enzymes and drug discovery: emerging opportunities[J]. Nat Rev Drug Discov, 2018, 17(1): 57-78.
|
18 |
Zhao B, Tsai YC, Jin B, et al. Protein engineering in the ubiquitin system: tools for discovery and beyond[J]. Pharmacol Rev, 2020, 72(2): 380-413.
|
19 |
Bernassola F, Chillemi G, Melino G. HECT-Type E3 ubiquitin ligases in cancer[J]. Trends Biochem Sci, 2019, 44(12): 1057-1075.
|